Arrowhead Pharmaceuticals Inc (ARWR)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$75.94
Buy
$78.98
$3.73 (+4.98%)
Prices updated at 26 May 2026, 21:52 EDT
| Prices minimum 15 mins delay
Prices in USD
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies desig ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Christopher Anzalone,PhD
CEO
Dr. Christopher Anzalone,PhD
Most recent earnings
30 Sep 2025
Fiscal year end
30 Sep 2025
Employees
711
Head office
177 E Colorado Boulevard
Pasadena
United States
91105
Key personnel
Owner name | Salary |
|---|---|
Dr. Michael S. Perry, PhD Independent Director | 0.09m |
Dr. Christopher Anzalone,PhD Chairman of the Board, Chief Executive Officer and President | 0.98m |
Dr. Mauro Ferrari, PhD Independent Director | 0.08m |
Dr. Adeoye Olukotun, M.D.,M.P.H. Independent Director | 0.08m |
Mr. Daniel Apel Chief Financial Officer and Principal Accounting Officer | 0.23m |
Mr. William D. Waddill Lead Independent Director | 0.10m |
Dr. Hongbo Lu, PhD Independent Director | 0.08m |
Ms. Victoria Vakiener Independent Director | 0.08m |
Mr. James Hamilton Chief of Discovery and Translational Medicine | 0.62m |
Mr. Patrick C. O'Brien Chief Operating Officer, General Counsel and Corporate Secretary | 0.65m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 21,318,582 |
| Vanguard Group Inc | 15,293,121 |
| BlackRock Fund Advisors | 11,538,029 |
| venBio Select Advisor LLC | 10,699,999 |
| FMR Inc | 7,266,652 |
Director dealings
Date | Action |
|---|---|
| 31 Dec 2025 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 05 Jan 2026 | - |
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 29 Dec 2025 | - |
| 29 Dec 2025 | - |
| 29 Dec 2025 | - |
Please note that past performance is not a reliable indicator of future returns.